LUND, Sweden--(BUSINESS WIRE)--Regulatory News: Probi (STO:PROB) has signed a business development agreement with Viva 5, a US probiotic specialist, granting them license rights within Consumer Healthcare for Probi Digestis® and Probi Defendum® in North America. Probi will work with Viva 5 to further strengthen its commercial position as well as the presence and consumer awareness of the Probi brand in the North American market place. Viva 5 and Probi are already engaged in commercial discussions with select US-based companies. The value of the US probiotic dietary supplements market is approximately USD 900 million. It is a highly fragmented market where products are sold through several...
0 Responses to Probi and Viva 5 Corporation form Probiotic Business Development Alliance in North America